Clinical trials: House Dust Mite Allergy
Allergy, Asthma
A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma
To demonstrate superiority of ALK HDM tablets versus placebo in immune response, measured as change of D.farinae specific immunoglobulin G4 (IgG4) from baseline to end of treatment with ALK HDM tablets given once daily over 60…
- Conditions
- Allergy, Asthma, Rhinitis
- Trial name
- NCT02596321
- Testing
- Mitizax
- Where
- 9 sites in Belarus, Russia
- Volunteers
- 112 people
- Sponsor
- Abbott
Rhinoconjunctivitis
House Dust Mite Observational Study
A Field Study to Observe Symptom Scores and Allergy Medication Usage in Subjects with a History of House Dust Mite-Induced Rhinoconjunctivitis
- Trial name
- NCT01949428
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Circassia Limited
Allergic Rhinitis Due to House Dust Mite, Allergic Asthma Due to Dermatophagoides Farinae
N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France
Non-interventional study to investigate the safety and tolerability of allergy immunotherapy ACARIZAX® 12 SQ-HDM in real-life clinical practice in adults patients (>18 years) with house dust mite allergy over a period of 12…
- Conditions
- Allergic Rhinitis Due to House Dust Mite, Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus
- Trial name
- CARIOCA (NCT03746860)
- Testing
- Tablet, Dispersible
- Where
- France
- Volunteers
- 1,508 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)
The purpose of this study is to evaluate the safety of two doses (6 Development Units [DU] and 12 DU) of MK-8237 sublingual tablets compared to Placebo in adolescents with house dust mite-induced allergic…
- Trial name
- NCT01678807
- Testing
- MK-8237 6 DU, MK-8237 12 DU
- Volunteers
- 195 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis, Allergic Rhinoconjunctivitis
PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis
The objective of the present study is to characterize the dose-response relationship of PURETHAL® Mites with a nasal provocation test in order to support the optimal dose in terms of clinical efficacy and safety.
- Trial name
- NCT01438463
- Testing
- PURETHAL Mites 6,667 AU/ml, PURETHAL Mites 20,000 AU/ml, PURETHAL Mites 50,000 AU/ml
- Where
- 35 sites in Austria, Belgium and 3 more
- Volunteers
- 290 people
- Sponsor
- HAL Allergy
Venous Thromboembolism, Atopic Dermatitis
The Incidence of Venous Thromboembolism in Atopic Dermatitis
This study aims to investigate the incidence of venous thromboembolism in people who are diagnosed with atopic dermatitis.
- Conditions
- Venous Thromboembolism, Atopic Dermatitis, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- NCT04969653
- Testing
- Exposure of venous thromboembolism
- Where
- United Kingdom
- Volunteers
- 754,745 people
- Sponsor
- Momentum Data
Perennial Allergic Rhinoconjunctivitis, House Dust Mite Allergy
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
The purpose of the study is to test the efficacy of the combination treatment AllQbG10 in patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy in a double-blind placebo-controlled setting
- Trial name
- NCT00574223
- Testing
- CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Cytos Biotechnology AG
Rhinoconjunctivitis
Phase II HDM-SPIRE Safety and Efficacy Study
The purpose of this study is to compare the treatment effect of three treatment regimens of HDM-SPIRE vs placebo and to evaluates the treatment effect of HDM-SPIRE on symptoms, rescue medication usage, Quality of Life and Sleep…
- Trial name
- NCT02150343
- Testing
- HDM-SPIRE
- Where
- 98 sites in United States, Canada and 6 more
- Volunteers
- 715 people
- Sponsor
- Circassia Limited
Allergy and Immunology
Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects
This is a single-center, randomized, double-blind, placebo-controlled, single-dose, dose- escalation study in otherwise healthy cat-, dust mite-, or Bermuda grass-allergic male and female subjects.
- Trial name
- NCT02559258
- Where
- Australia
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Tunitas Therapeutics, Inc.
Allergy
Safety of ToleroMune House Dust Mite (HDM) to Treat House Dust Mite Allergy in HDM Allergic Subjects With Rhinoconjunctivitis
The prevalence of allergic sensitisation to House Dust Mite (HDM) varies from region to region and depends on the regional prevalence of HDM.
- Trial name
- NCT01008332
- Testing
- Toleromune HDM
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Circassia Limited
Allergic Rhinitis, Allergic Rhinoconjunctivitis
MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)
The purpose of this study is to assess the effect on various biomarkers of treatment with MK-8237 in participants with allergic rhinitis or rhinoconjunctivitis.
- Trial name
- NCT01852825
- Testing
- MK-8237, NAC
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Adolescent Mite Allergy Safety Evaluation
This is a 28-day clinical trial studying the safety of the house dust mite tablet in adolescents with allergic rhinitis/rhinoconjunctivitis.
- Trial name
- AMASE (NCT04541004)
- Testing
- HDM SLIT-tablet
- Where
- 27 sites in Czechia, Germany and 1 more
- Volunteers
- 253 people
- Sponsor
- ALK-Abelló A/S
House Dust Mite Allergy
Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients
hdmASIT+TM product is based on highly purified allergen fragments from house dust mites. The purpose of this study is to assess the safety and clinical tolerability of subcutaneous immunotherapy with hdmASIT+TM in patients with…
- Trial name
- NCT03094845
- Testing
- hdmASIT+TM
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- ASIT Biotech S.A.
Allergy
Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America
This is a research study intending to look at the response of a specific type of allergy cells in the blood (called T cells) to a a type of immunotherapy product known as SPIREs (Synthetic Peptide Immuno-Regulatory Epitopes)…
- Trial name
- NCT02601690
- Testing
- Blood Sampling
- Where
- 2 sites in United States
- Volunteers
- 199 people
- Sponsor
- Adiga Life Sciences, Inc.
Allergic Rhinitis
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy
The objective of this clinical trial is to assess the safety and efficacy of sublingual application of allergen extracts for specific immunotherapy in patients suffering from perennial allergic rhinitis due to house dust mites.
- Trial name
- NCT01014325
- Testing
- Allergen extract
- Where
- Spain
- Volunteers
- 130 people
- Sponsor
- Roxall Medizin
Allergic Rhinitis, Asthma
Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and Asthma
To assess the impact of SQ SLIT-tablets (SQ Grass SLIT-tablet and SQ HDM SLIT-tablet) in Danish and Swedish allergic rhinitis (AR) patients, with or without asthma, between 2007-2020.
- Conditions
- Allergic Rhinitis, Asthma, Allergy
- Trial name
- RELY (NCT05476484)
- Testing
- SQ SLIT-tablet
- Where
- Denmark
- Volunteers
- 46,196 people
- Sponsor
- ALK-Abelló A/S
Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus
Mite Asthma Pediatric Immunotherapy Trial
The trial aims to demonstrate efficacy of the House Dust Mite SLIT-tablet versus placebo as add-on treatment in children and adolescents (5-17 years) with House Dust Mite allergic asthma based on clinically relevant asthma…
- Conditions
- Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
- Trial name
- MAPIT (NCT03654976)
- Testing
- HDM SLIT-tablet
- Where
- 64 sites in United States, Bulgaria and 7 more
- Volunteers
- 533 people
- Sponsor
- ALK-Abelló A/S
Perennial Allergic Rhinitis, Rhinitis, Allergic
Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers
Alleviation of allergic symptoms induced by house dust mites when using the medical device AM-301. This clinical investigation explored the efficacy and safety of AM-301 when used to reduce symptoms of house dust mite sufferers.
- Trial name
- NCT05122143
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Canada
- Volunteers
- 37 people
- Sponsor
- Altamira Medica Ltd.
Allergy
Sensitivity and Specificity of 3 Solutions of Allergen Extract for Diagnosis by Skin Prick Testing
A Phase III study to determine the sensitivity and specificity of three solutions of different allergen extracts for diagnosis by skin prick-test: 5 Grasses pollen, Birch pollen, Dermatophagoides pteronyssinus mite
- Trial name
- NCT01964768
- Testing
- Skin prick-test
- Volunteers
- 324 people
- Sponsor
- Stallergenes Greer
Asthma
Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)
Prolongation of the EPAAC™ trial - NCT00152464 (The Early Prevention of Asthma in Atopic Children). 36 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in young atopic…
- Trial name
- NCT00160563
- Testing
- LEVOCETIRIZINE
- Where
- 51 sites in Australia, Belgium and 8 more
- Volunteers
- 207 people
- Sponsor
- UCB Pharma